{"id":"W4380079804","doi":"10.1002/hon.3164_441","title":"CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Queen's University; Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Loxo Oncology; AbbVie Canada; National Institutes of Health; Pharmacyclics; National Comprehensive Cancer Network; Breast Cancer Research Foundation; TG Therapeutics; Regeneron Pharmaceuticals; Genentech; Celgene; Gilead Sciences","keywords":"Medicine; Salvage therapy; Internal medicine; Gemcitabine; Rituximab; Oncology; Follicular lymphoma; Lymphoma; Refractory (planetary science); Gastroenterology; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002557567,0.0002175734,0.0006614926,0.00008531513,0.0001150568,0.000008738235,0.0001327277,0.0002268591,0.0001134805],"category_scores_gemma":[0.0001866946,0.00009403728,0.0001241612,0.0003119831,0.0001968657,0.00004626363,0.00004694116,0.00006928749,0.00002392782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003134023,"about_ca_system_score_gemma":0.0003359419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009563202,"about_ca_topic_score_gemma":0.000008687784,"domain_scores_codex":[0.9984535,0.0001072563,0.000487762,0.0003480179,0.0002869645,0.0003164812],"domain_scores_gemma":[0.997917,0.00108123,0.0003216078,0.000334038,0.0002518255,0.00009431681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1175121,0.1685274,0.5552106,0.0007056231,0.001446903,0.000638265,0.001702936,0.00001093381,0.00116591,0.009660741,0.01763749,0.125781],"study_design_scores_gemma":[0.2607492,0.08724437,0.5593471,0.000159008,0.0002223088,0.0001206446,0.0003052536,0.0004693683,0.003449183,0.0002904813,0.08735108,0.000292045],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9262685,0.00001158417,0.00004502198,0.001154082,0.00009355046,0.07196572,0.00002482924,0.00008427988,0.0003524506],"genre_scores_gemma":[0.8650145,0.00001331112,0.0005032845,0.0004937515,0.00003075054,0.1335994,0.0000952295,0.00002249814,0.0002272238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.143237,"threshold_uncertainty_score":0.3834729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09117545114869888,"score_gpt":0.3840070893897315,"score_spread":0.2928316382410326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}